Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 9, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-016-0250-9
Keywords
-
Categories
Funding
- Henan Provincial Grant for Overseas Research for Young Leaders of Medical Technology [2014041]
- Natural Science Foundation of China (NSFC) [81201793]
- Division of Hematology and Oncology, New York Medical College
- Westchester Medical Center, Valhalla, NY, USA
Ask authors/readers for more resources
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
